These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34370574)

  • 1. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
    Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0133221. PubMed ID: 34370574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
    Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM
    ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985
    [No Abstract]   [Full Text] [Related]  

  • 4. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the activity of cefepime-taniborbactam against
    Mojica MF; Zeiser ET; Becka SA; LiPuma JJ; Six DA; Moeck G; Papp-Wallace KM
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0049823. PubMed ID: 37768313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
    Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
    BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
    Fraile-Ribot PA; Zamorano L; Orellana R; Del Barrio-Tofiño E; Sánchez-Diener I; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H
    J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409
    [No Abstract]   [Full Text] [Related]  

  • 13. The Class A β-Lactamase Produced by
    Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales.
    Vázquez-Ucha JC; Seoane-Estévez A; Rodiño-Janeiro BK; González-Bardanca M; Conde-Pérez K; Martínez-Guitián M; Alvarez-Fraga L; Arca-Suárez J; Lasarte-Monterrubio C; Gut M; Gut I; Álvarez-Tejado M; Oviaño M; Beceiro A; Bou G;
    J Antimicrob Chemother; 2021 May; 76(6):1498-1510. PubMed ID: 33677560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.
    Papp-Wallace KM; Becka SA; Taracila MA; Zeiser ET; Gatta JA; LiPuma JJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the AmpC β-Lactamase from Burkholderia multivorans.
    Becka SA; Zeiser ET; Barnes MD; Taracila MA; Nguyen K; Singh I; Sutton GG; LiPuma JJ; Fouts DE; Papp-Wallace KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012762
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.
    Canver MC; Satlin MJ; Westblade LF; Kreiswirth BN; Chen L; Robertson A; Fauntleroy K; La Spina M; Callan K; Jenkins SG
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.